scholarly journals Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor

2021 ◽  
Author(s):  
J.E. Fromme ◽  
P. Zigrino
Keyword(s):  
Prognostic Factor ◽  
Braf Mutation ◽  
Melanoma Metastasis ◽  
Connexin Expression

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

2009 ◽  
Vol 27 (35) ◽  
pp. 5931-5937 ◽  
Author(s):  
Susan D. Richman ◽  
Matthew T. Seymour ◽  
Philip Chambers ◽  
Faye Elliott ◽  
Catherine L. Daly ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Braf Mutation ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Progression Free Survival ◽  
Predictive Biomarker ◽  
Poor Prognostic Factor ◽  
Minimal Impact ◽  
The Impact

PurposeActivating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti–epidermal growth factor receptor (anti-EGFR) therapies in advanced colorectal cancer (aCRC). We wanted to determine whether KRAS and/or BRAF mutation is also a predictive biomarker for other aCRC therapies.Patients and MethodsThe Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing (MRC FOCUS) trial compared treatment sequences including first-line fluorouracil (FU), FU/irinotecan or FU/oxaliplatin in aCRC. Tumor blocks were obtained from 711 consenting patients. DNA was extracted and KRAS codons 12, 13, and 61 and BRAF codon 600 were assessed by pyrosequencing. Mutation (mut) status was assessed first as a prognostic factor and then as a predictive biomarker for the benefit of adding irinotecan or oxaliplatin to FU. The association of BRAF-mut with loss of MLH1 was assessed by immunohistochemistry.ResultsThree hundred eight (43.3%) of 711 patients had KRAS-mut and 56 (7.9%) of 711 had BRAF-mut. Mutation of KRAS, BRAF, or both was present in 360 (50.6%) of 711 patients. Mutation in either KRAS or BRAF was a poor prognostic factor for overall survival (OS; hazard ratio [HR], 1.40; 95% CI, 1.20 to 1.65; P < .0001) but had minimal impact on progression-free survival (PFS; HR, 1.16; 95% CI, 1.00 to 1.36; P = .05). Mutation status did not affect the impact of irinotecan or oxaliplatin on PFS or OS. BRAF-mut was weakly associated with loss of MLH1 staining (P = .012).ConclusionKRAS/BRAF mutation is associated with poor prognosis but is not a predictive biomarker for irinotecan or oxaliplatin. There is no evidence that patients with KRAS/BRAF mutated tumors are less likely to benefit from these standard chemotherapy agents.

scholarly journals BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

2011 ◽  
Vol 104 (5) ◽  
pp. 856-862 ◽  
Author(s):  
T Yokota ◽  
T Ura ◽  
N Shibata ◽  
D Takahari ◽  
K Shitara ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Braf Mutation ◽  
Recurrent Colorectal Cancer

scholarly journals RADI-13. IMPACT OF CITV AND BRAF MUTATION ON MELANOMA METASTASIS RESPONSE TO STEREOTACTIC RADIOSURGERY

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i24-i24
Author(s):  
Ali Alattar ◽  
Rushikesh Joshi ◽  
Brian HIrshman ◽  
Kate Carroll ◽  
Osamu Nagano ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Braf Mutation ◽  
Proportional Hazards ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Cox Proportional Hazards ◽  
Melanoma Metastasis ◽  
Mutation Status ◽  
Prognostic Assessment ◽  
Independent Cohort

Abstract INTRODUCTION: Survival prognostication is an important aspect of personalizing oncologic care for patients with melanoma brain metastasis (BM). We previous demonstrated the utility of a cumulative intracranial tumor volume modified diagnosis-specific graded prognostic assessment scale (CITV-dsGPA) for SRS-treated melanoma BM patients. Pertinent prognostic variables in this model included age, Karnofsky performance status (KPS), and CITV. Here we determined whether the incorporation of BRAF mutation status into this CITV-modified scale further enhanced its prognostic accuracy. METHODS: We collated the survival pattern of 331 melanoma BM patients with known BRAF mutation status treated with stereotactic radiosurgery (SRS) and validated our findings in an independent cohort of 174 patients. All patients with BRAF mutation were treated with BRAF inhibitors. The prognostic utility of the model with and without BRAF mutation information was compared using the net reclassification index (NRI &gt; 0) and integrated discrimination improvement (IDI) metric. RESULTS: Presence of the BRAF mutation was associated with a reduced hazard of death in univariate Cox proportional hazards survival analysis (hazard ratio (HR) 0.74, p&lt; 0.001). This effect persisted in a multivariate model that controlled for age, KPS, and CITV (HR 0.72, p&lt; 0.001). Addition of BRAF mutation status to the CITV-ds-GPA model for melanoma significantly improved its prognostic value, with NRI &gt;0 of 0.294 (p=0.01) and IDI of 0.017 (p=0.02). We validated these findings in an independent cohort of 174 melanoma patients. CONCLUSIONS: Optimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of age, KPS, CITV, and BRAF mutation status.

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy

2014 ◽  
Vol 50 (15) ◽  
pp. 2668-2676 ◽  
Author(s):  
Andrew P. Barbour ◽  
Yue Hang Tang ◽  
Nicola Armour ◽  
Ken Dutton-Regester ◽  
Lutz Krause ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Adjuvant Therapy ◽  
Braf Mutation ◽  
Independent Prognostic Factor ◽  
Stage Iiib ◽  
Mutation Status ◽  
Resected Stage

Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor

2021 ◽  
Vol 31 (5) ◽  
pp. 616-622
Author(s):  
Jordi Rubió-Casadevall ◽  
Anna Carbó-Bagué ◽  
Montserrat Puigdemont ◽  
Gemma Osca-Gelis ◽  
Gloria Oliveras ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cutaneous Melanoma ◽  
Braf Mutation ◽  
Population Based

Nutritional status as a prognostic factor in advanced head and neck cancer

1998 ◽  
Vol 23 (4) ◽  
pp. 376-376
Author(s):  
Quak ◽  
Van Bokhorst ◽  
Klop ◽  
Van Leeuwen ◽  
Snow
Keyword(s):  
Head And Neck Cancer ◽  
Prognostic Factor ◽  
Nutritional Status ◽  
Head And Neck ◽  
Neck Cancer ◽  
Advanced Head

405: Previous History of Bladder Cancer is an Independent Prognostic Factor for Upper Tract Transitional Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 135-135
Author(s):  
Eiji Kikuchi ◽  
Akira Miyajima ◽  
Ken Nakagawa ◽  
Mototsugu Oya ◽  
Takashi Ohigashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Previous History ◽  
Independent Prognostic Factor ◽  
Upper Tract ◽  
History Of

960: Is Race a Prognostic Factor of Prostate Tumor Burden and Outcome in the PSA Era: The Duke Experience 2006

2006 ◽  
Vol 175 (4S) ◽  
pp. 310-310
Author(s):  
Nicholas J. Fitzsimons ◽  
Leon L. Sun ◽  
Thomas J. Polascik ◽  
Vladimir Mouraviev ◽  
Craig F. Donatucci ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Tumor Burden ◽  
Prostate Tumor
Sign in / Sign up

Export Citation Format

Share Document